Better prognosis for early blast clearance in leukemia

October 24, 2012
Better prognosis for early blast clearance in leukemia
Patients with acute myeloid leukemia whose peripheral blood blasts clear in six days or less after chemotherapy have significantly better survival than patients whose peripheral blasts clear later, according to a study published in the Nov. 1 issue of Cancer.

(HealthDay)—Patients with acute myeloid leukemia whose peripheral blood blasts clear in six days or less after chemotherapy have significantly better survival than patients whose peripheral blasts clear later, according to a study published in the Nov. 1 issue of Cancer.

Martha Arellano, M.D., from Emory University in Atlanta, and colleagues investigated the association between time to peripheral blood blast clearance after and disease status in 162 patients with .

The researchers found that, 14 days after induction chemotherapy, marrow blast clearance was observed in 84 percent of 119 patients with early peripheral clearance (six days or less) and 60 percent of 43 patients with delayed peripheral clearance (greater than six days). After a median follow-up of 1,538 days, the early clearance group had significantly longer relapse-free survival (442 versus 202 days) and overall survival (930 versus 429 days). After controlling for multiple variables, early peripheral blast clearance was a significant predictor of marrow blast clearance at day 14, , and relapse-free and overall survival.

"Early clearance of peripheral blood blasts after induction chemotherapy predicts for early marrow blast clearance, complete remission, relapse-free survival, and overall survival," Arellano and colleagues conclude. "Early blood blast clearance provides reassuring information to patients early into the course of their therapy and prior to the availability of cytogenetic and , given the association with better relapse-free survival and overall survival."

Explore further: No survival advantage with peripheral blood stem cells versus bone marrow

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

No survival advantage with peripheral blood stem cells versus bone marrow

October 19, 2012
(Medical Xpress)—Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.